292 related articles for article (PubMed ID: 25976679)
1. Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.
Khatri R; Shah P; Guha R; Rassool FV; Tomkinson AE; Brodie A; Jaiswal AK
Mol Cancer Ther; 2015 Jul; 14(7):1728-37. PubMed ID: 25976679
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Nrf2-an update.
Niture SK; Khatri R; Jaiswal AK
Free Radic Biol Med; 2014 Jan; 66():36-44. PubMed ID: 23434765
[TBL] [Abstract][Full Text] [Related]
3. Antioxidant-induced INrf2 (Keap1) tyrosine 85 phosphorylation controls the nuclear export and degradation of the INrf2-Cul3-Rbx1 complex to allow normal Nrf2 activation and repression.
Kaspar JW; Niture SK; Jaiswal AK
J Cell Sci; 2012 Feb; 125(Pt 4):1027-38. PubMed ID: 22448038
[TBL] [Abstract][Full Text] [Related]
4. An auto-regulatory loop between stress sensors INrf2 and Nrf2 controls their cellular abundance.
Lee OH; Jain AK; Papusha V; Jaiswal AK
J Biol Chem; 2007 Dec; 282(50):36412-20. PubMed ID: 17925401
[TBL] [Abstract][Full Text] [Related]
5. Nrf2 signaling and cell survival.
Niture SK; Kaspar JW; Shen J; Jaiswal AK
Toxicol Appl Pharmacol; 2010 Apr; 244(1):37-42. PubMed ID: 19538984
[TBL] [Abstract][Full Text] [Related]
6. Oncogene PKCĪµ controls INrf2-Nrf2 interaction in normal and cancer cells through phosphorylation of INrf2.
Niture SK; Gnatt A; Jaiswal AK
J Cell Sci; 2013 Dec; 126(Pt 24):5657-69. PubMed ID: 24127568
[TBL] [Abstract][Full Text] [Related]
7. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Morandi A; Martin LA; Gao Q; Pancholi S; Mackay A; Robertson D; Zvelebil M; Dowsett M; Plaza-Menacho I; Isacke CM
Cancer Res; 2013 Jun; 73(12):3783-95. PubMed ID: 23650283
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 interaction with INrf2(Keap1) mediates stress-induced Nrf2 activation.
Niture SK; Jaiswal AK
J Biol Chem; 2010 Nov; 285(47):36865-75. PubMed ID: 20864537
[TBL] [Abstract][Full Text] [Related]
9. Expression of xCT and activity of system xc(-) are regulated by NRF2 in human breast cancer cells in response to oxidative stress.
Habib E; Linher-Melville K; Lin HX; Singh G
Redox Biol; 2015 Aug; 5():33-42. PubMed ID: 25827424
[TBL] [Abstract][Full Text] [Related]
10. GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
Abrhale T; Brodie A; Sabnis G; Macedo L; Tian C; Yue B; Serrero G
BMC Cancer; 2011 Jun; 11():231. PubMed ID: 21658239
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
12. INrf2 (Keap1) targets Bcl-2 degradation and controls cellular apoptosis.
Niture SK; Jaiswal AK
Cell Death Differ; 2011 Mar; 18(3):439-51. PubMed ID: 20865015
[TBL] [Abstract][Full Text] [Related]
13. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
14. Prothymosin-alpha mediates nuclear import of the INrf2/Cul3 Rbx1 complex to degrade nuclear Nrf2.
Niture SK; Jaiswal AK
J Biol Chem; 2009 May; 284(20):13856-13868. PubMed ID: 19279002
[TBL] [Abstract][Full Text] [Related]
15. Antioxidant-induced modification of INrf2 cysteine 151 and PKC-delta-mediated phosphorylation of Nrf2 serine 40 are both required for stabilization and nuclear translocation of Nrf2 and increased drug resistance.
Niture SK; Jain AK; Jaiswal AK
J Cell Sci; 2009 Dec; 122(Pt 24):4452-64. PubMed ID: 19920073
[TBL] [Abstract][Full Text] [Related]
16. Nrf2-induced antiapoptotic Bcl-xL protein enhances cell survival and drug resistance.
Niture SK; Jaiswal AK
Free Radic Biol Med; 2013 Apr; 57():119-31. PubMed ID: 23275004
[TBL] [Abstract][Full Text] [Related]
17. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
Shibata T; Kokubu A; Gotoh M; Ojima H; Ohta T; Yamamoto M; Hirohashi S
Gastroenterology; 2008 Oct; 135(4):1358-1368, 1368.e1-4. PubMed ID: 18692501
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
[TBL] [Abstract][Full Text] [Related]
19. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.
Shibata T; Ohta T; Tong KI; Kokubu A; Odogawa R; Tsuta K; Asamura H; Yamamoto M; Hirohashi S
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13568-73. PubMed ID: 18757741
[TBL] [Abstract][Full Text] [Related]
20. Nrf2:INrf2 (Keap1) signaling in oxidative stress.
Kaspar JW; Niture SK; Jaiswal AK
Free Radic Biol Med; 2009 Nov; 47(9):1304-9. PubMed ID: 19666107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
